BIOMARKERS IN THE SPECTRUM OF AUTOIMMUNE DISEASES

Objectives

  • Review current state of biomarkers for autoimmune diseases, including type 1 diabetes, multiple sclerosis, scleroderma, and systemic lupus erythematosis
  • Determine criteria for identification, development, and validation of biomarkers for disease risk, diagnosis, disease activity or stage, immune activity, and response to therapy
    • What are our gold standards?
    • What are the criteria and approaches for defining and validating a biomarker?
  • Discuss advantages and disadvantages of genetic, immunologic, inflammation, quality-of-life, and end-organ specific biomarkers for diagnosis, staging, and evaluation of therapy of autoimmune diseases in general and of specific diseases
  • Identify opportunities for potential new biomarkers for autoimmune diseases, research approaches to develop these, and pathways for transition of new biomarkers from basic research to clinical research to clinical practice
  • Evaluate the possibility for clinical trials for new agents for prevention and treatment of autoimmune disease to be done in a timely, cost-effective, and definitive manner with available biomarkers
  • Identify the roles of government, industry, academia, clinicians, and health care payers in the development and validation of new biomarkers

Agenda

Moderator: David S. Pisetsky, M.D., Ph.D., Duke University

Discussant: Elaine Collier, M.D., National Institute of Allergy and Infectious Diseases

Biomarkers in Lung Disease in Scleroderma
Barbara White, M.D., University of Maryland and Veterans Affairs Medical Center, Baltimore

Antigen-Specific Proliferation and Cytokine Expression as Surrogate Markers for Highly Specific and Global Immunotherapies of Autoimmune Diseases
Roland Martin, M.D., National Institute of Neurological Diseases and Stroke

Immunologic Staging of Multiple Sclerosis
Howard L. Weiner, M.D., Harvard University and Brigham and Women’s Hospital

Type 1 Diabetes Mellitus, Addison's Disease, and Celiac Disease
George S. Eisenbarth, M.D., Ph.D., University of Colorado Health Sciences Center

A Correlate Does Not a Surrogate Make: Autoantibodies and Beta-Cell Function in Prevention of Type 1 Diabetes
Carla J. Greenbaum, M.D., University of Washington

Biomarkers and Surrogate Endpoints in Systemic Lupus Erythematosus
Arthur Kavanaugh, M.D., University of Texas Southwestern Medical Center

Outcome Measures in Systemic Lupus Erythematosis Clinical Trials
Michelle Petri, M.D., Johns Hopkins University School of Medicine

Biomarkers in Rheumatoid Arthritis
David S. Pisetsky, M.D., Ph.D.

Discussant: Michael B. Stewart, M.D., Bristol-Myers Squibb

Overview  Agenda  Registration  Conference Abstracts
  Hotel & Travel  Selected References 
Remote Video Conference Participation  Contact  NIH Home Page